Diabetic cardiomyopathy

Diabetic cardiomyopathy is defined by the existence of abnormal myocardial structure and performance in the absence of other cardiac risk factors, such as coronary artery disease, hypertension, and significant valvular disease, in individuals with diabetes mellitus.

  • AstraZeneca’s Onglyza (saxagliptin)
  • AstraZeneca’s Kombiglyze (saxagliptin and metformin extended release)
  • Takeda’s Nesina (alogliptin)
  • Takeda’s Kazano (alogliptin and metformin)
  • Takeda’s Oseni (alogliptin and pioglitazone)

Related Conference of Diabetic cardiomyopathy

May 30-31, 2024

6th Euro Cardiology Congress

Vienna, Austria
May 30-31, 2024

39th World Congress on Heart Diseases

Vienna, Austria
June 20-21, 2024

5th European Summit on Cardiology Research

Dublin, Ireland
July 16-17, 2024

13th World Heart Congress

Paris, France
August 01-02, 2024

38th World Congress on Heart Diseases

Montreal, Canada
September 16-17, 2024

3rd Global Summit on Cardiology and Cardiac Surgery

Paris, France
September 19-20, 2024

6th Annual Conference on Vascular Medicine

London, UK
September 19-20, 2024

7th World Heart and Brain Conference

London, UK
October 17-18, 2024

8th Annual Heart Rhythm Conference

Barcelona, Spain
October 24-25, 2024

11th International Conference on Interventional Cardiology

Zurich, Switzerland

Diabetic cardiomyopathy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in